🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsRetatrutide & Triple AgonistsRetatrutide and fatty liver — MASH resolution rates in Phase 2 Page 5

Retatrutide and fatty liver — MASH resolution rates in Phase 2

MASHdoc_SA Mon, May 11, 2026 at 6:13 PM 23 replies 534 viewsPage 5 of 5
TrialTracker_MD
Senior Member
2,345
15,678
Jan 2024
Maryland
May 22, 2026 at 2:25 AM#21
stefan_berlin said:
Practical: whatever you change, write down the date and the reason.

Agreed on the substance. I would put less weight on the timescale, because two months of anything is not enough to distinguish a trend from a wobble.

Last edited: May 22, 2026 at 7:25 AM
21 19Dr.EM_Chicago, pete_RVA, CarlaRPh_TPA and 18 others
Reply Quote Save Share Report
PeptideChemSF
Senior Member
1,890
9,012
Jan 2024
San Francisco, CA
May 26, 2026 at 12:19 AM#22
stefan_berlin said:
Practical: whatever you change, write down the date and the reason.

Bookmarking. The distinction being drawn above is the one nobody else makes. Adding it to my notes with a link back to this thread.

22 20dave_SLC, FDA_TrackerJim, ricardo_MIA and 19 others
Reply Quote Save Share Report
Dr.LipidDallas
VIP Member
2,678
14,567
Dec 2023
Dallas, TX
May 29, 2026 at 10:10 PM#23

Adding the clinical framing, because it changes how the question reads. The useful move here is to separate what is established from what is widely repeated. Those two sets overlap less than the confident tone of most write-ups suggests, and the second set is where nearly all the disagreement on this board comes from.

Last edited: May 30, 2026 at 12:10 AM
23 21cory_ATX, lori_vegas, Dr.PulmRoch and 20 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
MikeKY_noInsulin
Member
267
1,234
Oct 2024
Louisville, KY
Jun 2, 2026 at 8:00 PM#24
Dr.LipidDallas said:
The useful move here is to separate what is established from what is widely repeated.

Second this. Nothing to add that would improve it.

Last edited: Jun 2, 2026 at 11:00 PM
24 22amy_econ_NJ, bbq_ray_KC, oliver_london and 21 others
Reply Quote Save Share Report
CryptoCarl
Member
789
3,456
May 2024
Arizona
Jun 6, 2026 at 5:47 PM#25
Dr.LipidDallas said:
The useful move here is to separate what is established from what is widely repeated.

There is a second half to this that has not been said yet. The mechanism and the magnitude are separate questions. Agreeing that something happens says nothing about whether it happens enough to act on.

Worth separating that from liver and MASH, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

Last edited: Jun 6, 2026 at 9:47 PM
25 23ChrisMacros, KetoKyle, CanadaChris and 22 others
Reply Quote Save Share Report
1345

Similar Threads

TRIUMPH-3 topline results — 24.2% body weight loss at 48 weeks10 replies
Retatrutide mechanism: GLP-1/GIP/glucagon triple agonism explained5 replies
Retatrutide Phase 2 dose-response analysis — optimal dose range10 replies
Glucagon receptor agonism and hepatic lipid oxidation — MASH implications13 replies
Retatrutide vs tirzepatide — dual vs triple agonist comparison22 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register